GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (LTS:0L49) » Definitions » Institutional Ownership

SCYNEXIS (LTS:0L49) Institutional Ownership : 33.21% (As of May. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is SCYNEXIS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, SCYNEXIS's institutional ownership is 33.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, SCYNEXIS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, SCYNEXIS's Float Percentage Of Total Shares Outstanding is 75.67%.


SCYNEXIS Institutional Ownership Historical Data

The historical data trend for SCYNEXIS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Institutional Ownership Chart

SCYNEXIS Historical Data

The historical data trend for SCYNEXIS can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 39.28 39.35 37.38 34.89 35.01 35.93 36.09 36.62 33.21 33.21

SCYNEXIS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


SCYNEXIS (LTS:0L49) Business Description

Traded in Other Exchanges
Address
1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

SCYNEXIS (LTS:0L49) Headlines

No Headlines